Sagimet Stock Surges as $175 Million Raise Sharpens Acne Drug Push
SAN MATEO, California, April 27, 2026, 13:03 PDT Sagimet Biosciences Inc. shares surged Monday, after the company set terms for a $175 million stock sale and signaled plans to funnel proceeds into a pivotal U.S. acne study for denifanstat—dermatology now takes priority in its pipeline. Sagimet is offering 29,166,700 Series A common shares at $6 each, targeting a closing date near April 28.
